Cerebrolysin for acute ischemic stroke

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 1, 2013, Pages 21-29

  Ziganshina, L E ^a   Abakumova, T R ^a  

^a KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Amino acids; Neuroprotective agents; Stroke

Indexed keywords

AMINO ACID; CEREBROLYSIN; NEUROPROTECTIVE AGENT;

CEREBROVASCULAR ACCIDENT; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

AMINO ACIDS; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84890402094     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v68i1.533     Document Type: Article

References (80)

1. AHA. American Heart Association. Heart and Stroke Disease Statistics. 2007; http://www.xmarks.com/site/www.americanheart.org/presenter. jhtml%3Fidentifier=3003499.
2. Bonita R Epidemiology of stroke. Lancet. 1992;339: 342-344.
3. Bonita R., Stewart A., Beaglehole R. International trends in stroke mortality: 1970-1985. Stroke. 1990; 21: 989-992.
4. French B., Forster A., Langhorne P. et al. Repetitive task training for improving functional ability after stroke. Cochr. Database of Syst. Rev. 2006; (3).
5. World Health Organization. The Atlas of Heart Disease and Stroke. 2007; http://www.who.int/cardiovasculardiseases/resources/atlas/en/
6. Gusev E.I., Skvortsova V.I., Stakhovskaia L.V. Epidemiology of stroke in Russia. Zhumal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2003; 8: 4-9.
7. Vilenskii B.S., Iakhno N.N. The problem of cerebral stroke: Its contemporary state. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2006;9-10:18-24.
8. Sandercock P.A.G., Counsell C, Gubitz G.J., Tseng M.C. Antiplatelet therapy for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2008;(3).
9. Wardlaw J.M., Murray V, Berge E., Zoppo G.J. et al. Thrombolysis for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2009;(4).
10. Mielke M., Wardlaw J., Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004;4.
11. Righetti E., Celani M.G., Cantisani T. et al. Glycerol for acute stroke. Cochr. Database of Syst. Rev. 2004;2.
12. Liu M., Counsell C, Zhao X.L., Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2003;3.
13. Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2001;4.
14. Gandolfo C, Sandercock P., Conti M. Lubeluzole for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002;1.
15. Horn J., Limburg M. Calcium antagonists for acute ischemic stroke. Cochr. Database of Syst. Rev. 2000;1.
16. Asplund K. Haemodilution for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002;4.
17. Muir K.W., Lees K.R. Excitatory amino acid antagonists for acute stroke. Cochr. Database of Syst. Rev. 2003;3.
18. Gubitz G., Sandercock P., Counsell C. Anticoagulants for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004;3.
19. Berge E., Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002;4.
20. Ricci S., Celani M.G., Cantisani A.T., Righetti E. Piracetam for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2006;2.
21. Shuaib A., Lees K.R., Lyden P. et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007; 357 (6): 562-571.
22. Ciccone A., Santilli I. Glycoprotein Ilb-IIIa inhibitors for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2006;4.
23. Zeng X., Liu M., Yang Y. et al. Ginkgo biloba for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2005;4.
24. Leonardi-Bee J., Steiner T., Bath-Hextall F. Naftidrofuryl for acute stroke. Cochr. Database of Syst. Rev. 2007;2.
25. Sandercock P., Counsell C, Tseng M.C. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin foracute ischaemic stroke. Cochr. Database of Syst. Rev. 2008;3.
26. Bath P.M.W., Bath-Hextall F.J. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004;3.
27. Bath P.M.W. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004;3.
28. Bereczki D., Fekete I., Prado G.F., Liu M. Mannitol for acute stroke. Cochr. Database of Syst. Rev. 2007; (3).
29. Bath P.M.W., Willmot M., Leonardi-Bee J., Bath-Hextall F.J. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochr. Database of Syst. Rev. 2002;4.
30. Blood Pressure in Acute Stroke Collaboration (BASC). Vasoactive drugs for acute stroke. Cochr. Database of Syst. Rev. 2000;4.
31. Blood Pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke. Cochr. Database of Syst. Rev. 2001;3.
32. Bath P.M.W. Prostacyclin and analogues for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2004;3.
33. Bereczki D., Fekete I. Vinpocetine for acute ischaemic stroke. Cochr. Database of Syst. Rev. 1997; (4).
34. Qizilbash N., Lewington S.L., Lopez-Arrieta J.M. Corticosteroids for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2002;3.
35. Candelise L., Ciccone A. Gangliosides for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2001;4.
36. Alvarez X.A., Lombardi V.R., Corzo L. et al. Oral cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J. Neur. Transmission. 2000;59 (Suppl.): 315-328.
37. Fragoso Y, Dantas D.C. Cerebrolysin for Alzheimer's disease. Cochr. Database of Syst. Rev. 2002;3.
38. Schauer E., Wonski R., Patockova J. et al. Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: Post lesion application indicates a wide therapeutic window. J. Neur. Transmission. 2006;113(7):855-868.
39. Riley C, Hutter-Paier B., Windisch M. et al. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J. Neur. Transmission. 2006; 113 (1): 103-110.
40. Makarenko A.N., Kositsin N.S., Nazimov I.V. et al. A comparative study of antistroke activity of the new drug «cerebral» and its fractions in rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2005; 68 (2): 15-20.
41. Sapronov N.S., Bul'on V.V., Kuznetsova N.N., Selina E.N. The neuroprotector effect of a new taurine derivative on a model of compression spinal cord trauma in rats. Eksperimental'naia i Klinicheskaia Farmakologiia. 2005; 68 (6): 45-48.
42. European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke, Third report of an Ad Hoc Consensus Group Meeting. Cerebrovasc. Dis. 2008; 8: 59-72.
43. Wahlgren N.G., Ahmed N. Neuroprotection in cerebral ischaemia: Facts and fancies - the need for new approaches. Cerebrovasc. Dis. 2004;17 (Suppl. 1): 153-166.
44. Chukanova E.L. The effect of cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2005; 105 (1): 42-45.
45. Gromova O.A., Tret'iakov V.E., Moshkovskii S.A. et al. An oligopep-tide membrane fraction of cerebrolysin. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2006; 106 (7): 68-70.
46. Onishchenko L.S., Gaikova O.N., Ianishevskii S.N. Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs. Morfologiia. 2006; 130 (6): 40-46.
47. Gafurov B.G., Alikulova N.A. Clinical and pathogenetical peculiarities and treatment policy in ischemic stroke of elderly and old age. Thumal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2004; 104 (Suppl. 11): 44-46.
48. Ladurner G., Kalvach P., Moessier H. The Cerebrolysin Study Group, Neuroprotective treatment with cerebrolysin in patients with acute stroke: A randomised controlled trial. J. Neur. Transmission. 2005;112:415-428.
49. Skvortsova V.I., Stakhovskaya L.V., Gubsky L.V. et al. A randomised, double-blind, placebo-controlled study of cerebrolysin safety and efficacy in the treatment of acute ischaemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 2004; 0(11): 51-55.
50. WOng G.K., Zhu X.L., Poon W.S. Beneficial effect of cerebrolysin on moderate and severe head injury patients: Result of a cohort study. Acta Neurochirurgica Supplement. 2005; 95: 59-60.
51. Review Manager (RevMan) [Computer program]. The Nordic Cochrane Centre. The Cochrane Collaboration, Copenhagen. 2008. Version 5.0.
52. Cuparnecu B. Efficacy of cerebrolysin in patients with ischaemic stroke of the middle cerebral artery. Pharmacol. Toxicol. 2001;89 (Suppl. 1): 136.
53. Haffner Z. Cerebrolysin in acute ischemic stroke. Stroke Trials Directory. Internet Stroke Center. 2001; www.strokecenter.org/trials/
54. Haffner Z., Gmeinbauer R., Moessler H. A randomized, double-blind, placebo-controlled trial with cerebrolysin in acute ischaemic stroke. Cerebrovasc. Dis. 2001;11 (Suppl. 4): 76.
55. Hong Z., Li X.W., Chen Q.T. et al. Re-evaluation of cerebrolysin in treatment of early rehabilitation after ischemic stroke. Chinese J. New Drugs and Clin. Remed./Zhongguo Xinyao Yu Linchuang Zaz. 2002; 21 (3): 133-136.
56. Hong Z., Zhu G., Chen H. The clinical efficacy of cerebrolysin in the treatment of acute ischemic stroke. Chinese J. Geriatric Heart Brain and Vessel Dis. 2005; 7 (5): 331-333.
57. Jin J.B. Efficacy of treating cerebral apoplexy with xingnaojing compared with cerebrolysin, a report of 96 cases. Clin. Medicine/Lin chuangyixue. 1999; 19 (9): 53-54.
58. Kulchikov A.E., Makarenko A.N. Neuroimmunocorrective activity is a future for neuroprotective agent cerebrolysin. Int. J. Stroke. 2008;3 (Suppl. 1): 324-325.
59. Kulchikov A.E., Makarenko A.N. The use of neuropeptides as neuroimmunocorrection agents in stroke induced viral complications. Int. J. Stroke. 2008; 3 (Suppl. 1): 456.
60. Makarenko A.N., Kulchikov A.E. Treatment of infection complications of the acute stroke by cerebrolysin. Int. J. Stroke. 2006; 1 (Suppl. 1): 81.
61. Ren J., Qiu Z., Du Z., Fan L. Effect comparison of injection disodium cytidine triphosphate and cerebrolysin in treatment of acute cerebral vascular disease. China Pharmacist. 2002; 5 (1): 45-46.
62. Sagatov D.R. Use of emoxepin in the treatment of ischemic stroke in young adult patients. Int. J. Stroke. 2008; 3 (Suppl. 1): 123.
63. Shamalov N.A., Stakhovskaya L.V., Gubsky L.V. et al. Effects of the neuroprotective drug cerebrolysin on the infarct volume after acute ischemic stroke. Cerebrovasc. Dis. 2005; 19 (Suppl. 2): 107.
64. Skvortsova V.I., Stakhovskaya L.V., Gubsky L.V. et al. Randomised, double-blind, placebo-controlled study of cerebrolysin safety and efficacy in the treatment of acute ischaemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 2004; 0 (11): 51-55.
65. Skvortsova V.I., Shamalov N.A., Moessler H., Novak P.H. Beneficial effects of the neurotrophic drug cerebrolysin on the infarct volume after acute stroke. Cerebrovasc. Dis. 2008; 25 (Suppl. 2): 145.
66. Skvortsova V.I., Shamalov N.A., Moessler H., Novak P.H. Positive impacts of the neurotrophic drug cerebrolysin on the infarct volume after acute stroke. Int. J. Stroke. 2008; 3 (Suppl. 1): 137.
67. Skvortsova V.I., Shamalov NA, Stakhovskaya L.V. et al. Cerebrolysin in acute ischaemic stroke: Results of randomised, double blind, placebo-controlled study. Cerebrovasc. Dis. 2005; 19 (Suppl. 2): 76.
68. Vilensky B.S., Odinak M.M., Shirokov E.A. et al. Experiencewith endolumbar application of cerebrolysin in hemispheric ischemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 2000; 100 (11): 31-34.
69. Vilensky B., Vinogradov O., Kuznetsov A. et al. Favorable influence of repeat cerebrolysin application in stroke patient rehabilitation. Int. J. Stroke. 2006; 1 (Suppl. 1): 170.
70. Wang H.T. The analysis of the efficacy of insulin, cerebrolysin, nitrendipine in the treatment of cerebral infarction. Practical Geriatrics. 1997; 11: 135-136.
71. Wu X. Urokinase therapy in acute ischemic stroke. Proceedings of the 4th Chinese Stroke Conference. China. Chengdu. 1995. p. 149-150.
72. Yavorskaya VA, Bondar O.B. Clinical features of cerebrolysinum application in patients in acute period of ischemic stroke. Int. J. Stroke. 2008; 3 (Suppl. 1): 141.
73. Zhang Q.Y., Xiong J., Wang R. Study on the effectiveness of cere-brolysin in 27 patients with cerebral infarction. Chinese J. Pharmacoepidemiology. 1994; 3 (4): 181-182.
74. Moher D., Schulz K.F., Altman D.G. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357:1191-1194.
75. Ziganshina L.E, Abakumova T, Kuchaeva A. Cerebrolysin for acute ischaemic stroke. Cochr. Database of Syst. Rev. 2010;4.
76. Shi Y.-M. Cerebrolysin in acute cerebral hemorrhage. Chinese J. Nerv. Ment. Dis. 1990;16(4): 228-230.
77. Zhang S.H., Lu X.M. Nursing care of the patient with cerebral infarction and aphasia receiving carotid internal drug injection and early speech training. J. Nurs. Sci. 1997; 12 (1): 34-35.
78. Zhu G.-X., Hong Z., Yao J.-L. Yu L.-Y. Double-blind and randomised placebo-controlled trial of cerebrolysin in improvement of nerve function and living ability in patientswith ischemic stroke. Chinese J. Clin. Rehabil. 2003; 7 (22): 3084-3085.
79. Ladurner G., Gmeinbauer R., Moessler H. Cerebrolysin in acute ischaemic stroke: A randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovasc. Dis. 2001; 11:75.
80. Ladurner G. Neuroprotection in acute ischaemic stroke. Stroke. 2001; 32:323.